Winning the Biosimilars Market: Strategic Imperatives for Sustainable Growth

Introduction:

Ask a biosimilars executive how the U.S. market feels right now, and the metaphor arrives before the sentence finishes: a bloodbath. It is not hyperbole. Within twelve months of the first adalimumab biosimilar reaching American patients in January 2023, the net price per prescription for the reference product and its copies fell by 43 percent — from roughly $5,007 to $2,837 per prescription. That is not erosion. That is a cliff. And it happened to Humira, the best-selling drug in the history of the industry, a franchise that has generated more than $200 billion in cumulative global sales since 2002.

For the C-suite, the lesson is uncomfortable but clarifying. The biosimilars opportunity is real and expanding — the global market is on a path from roughly $42 billion in 2025 to well above $150 billion within a decade. But the economics reward a very specific kind of operator. The companies bleeding out are the ones that treated biosimilars like a slightly harder generics play. The companies winning are the ones that understood, early, that this is a game of contracting leverage, manufacturing scale, and therapeutic-area selection — not molecules alone.

The distinction matters because the capital at stake is enormous and the failure mode is quiet. No one announces that they lost the biosimilars war; they post a soft quarter, defer a launch, and let a product line fade. Meanwhile a handful of operators — Sandoz, Samsung Bioepis, Amgen, Celltrion, Biocon — keep compounding share and adding molecules. What follows is what those winners are doing differently, grounded in what the first three years of open adalimumab competition actually revealed, and translated into decisions a board can act on this cycle.

‘’Net prices are collapsing, share is changing hands by the quarter, and the winners look nothing like the winners of the generics era.’’

The Price Cliff Is the Business Model

Start with the number that should anchor every strategy conversation. In the four quarters following the first adalimumab launch, net sales for the molecule dropped roughly 45 percent — from about $5 billion to $2.8 billion per quarter — even as total prescription volume held essentially flat at around one million per quarter. Demand did not fall. Price did. The entire value shift went to payers and, eventually, patients.

There is a counterintuitive detail buried in that first year that every executive should internalize: for several quarters, the reference product was actually cheaper on a net basis than its own biosimilars. By Q4 2023, Humira's net price per prescription sat near $2,798, below a biosimilar range of roughly $3,452 to $4,793. The originator, armed with deep rebate relationships and formulary muscle, simply out-discounted the newcomers to defend share. This is the single most important dynamic in the U.S. market and the one that most surprises teams coming from a generics background: list price is theater; net price is the war. A biosimilar can carry a wholesale acquisition cost 85 percent below the originator — as Hadlima, Yusimry, and Simlandi have — and still lose the formulary because the incumbent's rebate wall is higher.

This is why so many entrants misread their own first-year results. A team that launches at an 85 percent WAC discount and watches share barely move often concludes the product failed. In reality the product was never the variable. The originator held the formulary by paying a larger rebate out of a still-enormous margin, betting — correctly, in most cases — that it could bleed the challenger's cash reserves faster than the challenger could bleed its share. The manufacturers that plan for this from day one price and provision capital for a multi-year siege, not a launch quarter. The ones that model a clean, generics-style ramp are the ones writing down inventory eighteen months later.

Share Is Moving — Just Not Where List Prices Point

If the first year was about price, the second and third are about share migration. And here the picture brightens for biosimilar developers. Across all forms of rheumatoid arthritis, the originator's slice of total adalimumab use has slipped from roughly 70 percent toward a market that analysts expect to reach a 50/50 split. In advanced rheumatoid arthritis specifically, biosimilar share climbed from around 3 percent at the end of 2023 to 10 percent a year later, while the branded drug slid from 22 percent to 16 percent.

The winner among adalimumab biosimilars is instructive. Hyrimoz emerged as the rheumatologist's default — but not, according to the physicians surveyed, because of any clinical preference. It won on payer dynamics and familiarity. Sandoz signed a private-label agreement with Cordavis, the CVS subsidiary built to commercialize biosimilars, and Hyrimoz became the first product under that label at a list price roughly 80 percent below Humira's. The molecule did not win the market. The contract did. That is the through-line of every biosimilar success story in the United States, and it is why the org chart of a winning biosimilar company looks more like a managed-markets shop than a research house.

Not All Molecules Bleed Equally

Here is where strategy separates survivors from casualties. Biosimilar uptake in the U.S. is wildly uneven by therapeutic area, and the difference is worth billions. Provider-administered products — the ones billed under the medical benefit, where buy-and-bill economics and a CMS reimbursement of the originator's ASP plus a premium create a genuine incentive to switch — have converted fast. Oncology, ophthalmology, and pegfilgrastim biosimilars reached an average of 81 percent share within five years of launch. Trastuzumab, bevacizumab, and rituximab all sit in the 76 to 90 percent range.

Contrast that with the pharmacy-benefit, self-administered categories — immunology, insulin, filgrastim, epoetin — where adoption has crawled to a fraction of the same level. The mechanism is not mysterious. When a biosimilar runs through the pharmacy benefit, the rebate-and-PBM machinery that protects incumbents is fully engaged, and switching friction is high. When it runs through the medical benefit, the provider has a direct economic reason to choose the lower-cost option. The benefit design, not the biology, predicts the outcome.

Case Study: One Molecule, Two Fates

Here is the detail that ties both stories together and should reframe how executives think about "the asset." The Humira biosimilar that Coherus valued at just $40 million on the way out the door — Yusimry — went on to capture something like a third of the rheumatology biosimilar market. How? Not through a PBM formulary, but through Mark Cuban's Cost Plus Drug Company, which sold it direct to consumers at a transparent, deeply discounted price, bypassing the rebate machinery entirely. The same molecule that was a rounding error inside a traditional PBM-dependent model became a genuine player once it was matched to a channel that fit it.

The molecule did not change. The route to market did. That is the whole thesis of this article compressed into a single product: in U.S. biosimilars, the commercial architecture around the drug determines the outcome far more than the drug.

The Fight Starts Years Before the Launch

There is a temptation to treat the price war as the whole story. It is only the visible half. The invisible half — the one that decides who even gets to the starting line — is the patent thicket. Humira is the textbook case: the originator layered well over a hundred patents around a single molecule, stretching protection far beyond the core composition and forcing challengers into settlements that delayed U.S. entry for years. Europe saw adalimumab biosimilars in 2018. American patients waited until 2023. That five-year gap was not science. It was strategy.

For an executive planning a portfolio, the implication is that legal and regulatory timing is a core commercial input, not a back-office function. The value of a biosimilar asset is a function of when it can actually launch, how many competitors reach the market in the same window, and whether an interchangeability designation — still rare, and commercially decisive for pharmacy-benefit products — is achievable. The U.S. has now cleared more than sixty approvals and forty-plus launches, and the pace of FDA clearances is accelerating, with batches of approvals arriving across oncology, immunology, and bone-health molecules. But the manufacturers capturing the upside are the ones that mapped the patent estate and the competitive launch window before committing development dollars, not after.

The Pie Is Growing Faster Than the Margins Shrink

It would be easy to read the price data and conclude the category is a value trap. That would be a mistake. Loss-of-exclusivity events are accelerating, the pipeline is broadening into complex biologics, and the total market is compounding at roughly 18 percent a year on most credible forecasts — pushing toward the $150–190 billion range by the mid-2030s. North America alone accounts for roughly 40 percent of global demand today.

The concentration tells its own story. The top ten firms control roughly 70 percent of the market, yet that headline masks divergent strategies. Samsung Bioepis has crossed a trillion Korean won in sales with a focused portfolio and has launched eleven biosimilars in the U.S. as of early 2026, with a stated ambition of twenty by 2030. Sandoz leads on breadth with roughly a 13 percent share and a diversified hospital-and-specialty book. The lesson for a CEO weighing entry is that both scale and focus can win — but hedging in the middle loses. A specialized player limiting internal competition for capital moves faster than a diversified giant forever choosing between a biosimilar and a higher-margin novel asset.

The Winner's Playbook

Strip away the noise and the companies pulling ahead share a recognizable operating logic. For executives allocating capital this cycle, five moves separate the winners from the wounded:

Own the contract, not just the molecule. The private-label and PBM-subsidiary route — Cordavis, and the payer-owned biosimilar vehicles following it — is where U.S. share is actually decided. Build managed-markets capability before you build a fifth pipeline asset.

Select for reimbursement pathway. Weight the portfolio toward buy-and-bill, medical-benefit molecules where switching economics favor the challenger. Enter pharmacy-benefit categories only with a credible rebate and formulary strategy in hand.
Treat manufacturing as the moat. When net prices fall 40-plus percent in a year, cost of goods is destiny. The players investing in high-yield process, digital-twin monitoring, and AI-driven production are buying the margin headroom that lets them survive the next price war.

Differentiate on formulation and service. High-concentration, citrate-free presentations, device advantages, cold-chain and storage edges, and patient-support infrastructure are the tiebreakers once price parity is reached. They are cheap relative to a molecule and they move real share.

Sequence for durability, not the first launch. The originator can out-discount you in year one. Capital structure and portfolio depth determine whether you are still standing in year three to collect the share that migrates once the incumbent's defense fatigues.

The Bottom Line for the Boardroom

Biosimilars are a bloodbath in exactly the way a well-functioning market is supposed to be: prices are falling toward marginal cost, savings are reaching the health system, and the operators who mistook this for a gentler version of generics are being carried off the field. But a bloodbath is not the same as a losing market. The volume is enormous and growing, the pathway advantages are learnable, and the winners are already visible — the ones who bring contracting leverage, manufacturing discipline, and therapeutic-area judgment to a fight that molecules alone will never win.

For the American C-suite, the strategic question has narrowed to something almost simple. You are not deciding whether biosimilars will reshape the biologics economy; that verdict is in. You are deciding whether your organization is built to win the specific fight this market rewards — or whether you are bringing a generics playbook to a knife fight. The companies that answer honestly, and reallocate accordingly, will find that the bloodbath was the best entry point they will ever get.